www.breastcancer-cured.com
Breast Cancer - Cured
Women for Breast Cancer Truth
Allopathic Oncology:
The Nature of Corporate Medicine
Fabrizio Taliano MD, PhD.

2007 Los Angeles
North American visit
Lecture/discussion session
with over 100 executives of
Investment Groups and
Venture Capital Funds
LECTURE 5

    Good afternoon, Ladies and Gentlemen,

    Thank you for inviting me to your great country, and for so generously funding my trip.
    This will enable me to meet American colleagues whom, so far, I only know through phone
    conversations. I look forward to these meetings with great pleasure. Thank you again.

    What I wish to discuss with you today is not something new. Several years ago I
    published an article in Rome of similar content, and I must have done a good job, because,
    as a result, there had been an attempt to drag me to court and sue me. Fortunately, the
    judge dismissed the case. Afterwards, I have received some threatening emails. So, you
    see, these ideas have been around for awhile, but I think this is a good time to bring them
    up again, and perhaps develop them into an action plan.

    I want to focus on the role and the position of oncology, both in Italy, and here, in the
    United States.

    It would be a mistake to try to determine and analyze the fundamental nature of allopathic  
    oncology based on our perception of it as a medical specialty. It is, of course, a branch of
    the medical profession, and the primary concern of its members should be the health and
    well-being of their patients. However, if we choose this premise as our starting point, our
    inquiry would lead us to utter confusion.

    The only valid point of observation for such an evaluation is the analysis of the behavior of
    oncology; the manner in which it functions, its goals, its policy and its ideology. Yes,
    surprising as it may seem, oncology has its own goals, it has a corporate policy, and it is
    guided by the principles of a well defined, if not easily recognised, ideology. If we
    approach it this way, we find that orthodox oncology is a corporate business model. As
    such, its strategy is brilliant, its methods very successful, and its principles utterly ruthless.
    We must forget that we are dealing with physicians, because they, themselves, have
    chosen to forget it a long time ago. Every oncologist is a corporate executive, a marketing
    and public relation representative of a corporate enterprise.

    If you use this as a model, suddenly all the anomalies and bizarre aspects of the cancer
    scenario fall into place, and become understandable.

    As any corporate enterprise, oncology has its market, and it offers services and goods that
    the market needs. It is not a humanistic enterprise. Its main concern is similar to that of
    the disease it is supposed to treat: It wants to grow, and spread, until it engulfed the
    whole social organism. And, similarly to cancer, it alienates itself from the host body, that
    is, society, to pursue its own specific objectives. It is not concerned about public health; it
    has its own agenda. This is a medical group that somewhere along the line left behind the
    Hippocratic oath. It is a quaint myth that medical doctors solemnly swear not to do harm.
    They don't do that since many decades.

    The cancer industry used to be a billion dollar business. It is now in the trillion dollar
    category, and still growing in leaps and bounds. As a business, it is in very good health.
    When a commercial enterprise reaches such dizzying heights, all moral considerations tend
    to become abstract, unrealistic concepts. The reality, the central factor on which all
    members must concentrate is the principle of the corporate profit, translated into very
    generous individual shares. This is the oncological corporate ideology, and it has proven
    itself to be very successful.

    Oncology, as a business enterprise, defines itself by its relationship to its market. As any
    other corporation, it wants to see its market grow, it wants to ensure as much repeat
    business as possible, and it wants to establish the highest possible profit on its services
    and goods. With a legitimate business, this is as far as the definition goes. With oncology,
    something else has been added.

    Oncology provides diagnostic procedures and treatments for cancer. These medical
    methods are legal, but not in the traditional sense of the term. The cancer establishment
    managed to purchase legal immunity in the guise of approval and legality for protocols that
    are obsolete, ineffective, and cancer causing. This is not a personal observation. In the
    course of this lecture, we will take a close look at the matter.

    To simplify things, we will limit our analysis to the field of breast cancer treatment. Breast
    cancer behaves like an epidemic; it is the fastest growing disease among women in
    industrialized countries.

    The three fundamental therapeutic principles concerning breast cancer are prevention,
    treatment, and follow-up monitoring. Let us examine each area both from the medical and
    from the corporate point of view, and we will find that what makes no sense at all
    medically, makes excellent sense financially. We will also realize that there is an
    irreconcilable contradiction between the needs of cancer patients, and the corporate
    objectives of oncology.

    Let us consider prevention. We are not looking at diet, supplements, life style. For an
    oncologist, these are alien concepts. The only tool of prevention that is recognized by
    oncology is screening. And here we arrive at an interesting situation.

    If we introduce into the cancer equation a screening process that is safe, accurate and
    very precise, and we apply this preventive technique among women from an early age,
    let's say, 14 years of age, then something quite remarkable would happen. Within a single
    generation, even sooner, breast cancer would be wiped out as a life threatening disease. It
    would be detected at a microscopic level, when it is only an immature, preliminary
    formation, and dealt with as easily as one deals with a mild cold.

    This strategy would be the equivalent to corporate suicide, as far as oncology is
    concerned. If we succeed to prevent cancer, we also eliminate one of the world's most
    lucrative medical enterprises. Anyone who believes that a trillion dollar corporate giant is
    going to let that happen without a fight, is incredibly naive.

    Just how much money are we talking about? Here, in your country, the average cost of
    dying of cancer, from the moment of diagnosis till the moment of death, is around 2-300
    thousand dollars. There are millions of Americans at various stages of cancer. Some in
    intensive care, some under periodic maintenance treatments, but all within a system where
    every day, every hour, every move and gesture costs a small fortune. Do your arithmetics,
    and you will arrive at astronomical figures, similar to the profits of oil companies, car
    manufacturers, and defense contractors.

    If oncology wants to remain healthy and profitable, it must formulate its method of cancer
    screening accordingly. The procedure must be unreliable, it should, preferably, be cancer
    causing, and profitable. It should not be able to detect cancer earlier than the stage where
    it is already sufficiently advanced to require surgery, high dose chemotherapy and
    radiation.

    Stated in such manner, the description of this policy sounds like a farce. However, it is
    anything but a joke. It is dead serious. It has been implemented a long time ago. The
    method is being hailed as the saviour of women. Regulatory agencies have approved its
    use, politicians make speeches about its benefits, and oncologists promote it as an
    essential test for all adult women, at all ages. The method is called mammography, and the
    procedure, a mammogram.

    It is painful, harmful, unreliable, and expensive. Cancer organizations (generously funded
    by the cancer industry), the mass media, and the medical establishment all sing praises of
    it. Medical analysts, statisticians, research scientists and courageous physicians all over the
    world are condemning it as a profit driven, harmful and counterproductive medical hoax.
    So, the question is, how can a medical procedure, like mammography, survive and prosper?

    This is, where we arrive at the concept of purchased legality. Mammograms are legal, not
    because they are beneficial, but because the regulators and law makers have been bought.
    The public is flooded with expert advice concerning the advantages of regular screening,
    and the dangers of not participating in the mammograph program. They are citing studies
    that are flawed and doctored, and they tell women that their chances of survival depend
    on undergoing mammogram examinations.

    The voice of the cancer industry is overwhelmingly powerful, and it is everywhere. Studies,
    favorable to mammography, are generously funded and rewarded. Scientific papers that
    prove its dangers and shortcomings are suppressed, their authors labeled as quacks or
    worse, and a never ending line of highly placed experts are quoted in support of the
    practice.  Meetings, marches and drives are organized in the name of breast cancer
    awareness, all directed towards the promotion of mammography. Women are told in no
    uncertain terms that if they refuse the screening, it will be their own fault if they develop
    breast cancer. The fact that this is absolute nonsense, and nothing but a corporate
    marketing scheme, cannot be explained to the public, partly because nobody is willing to
    finance such a publicity campaign, and partly because the mass media rejects anything that
    is against mammograms. The politically correct, financially rewarding, and socially accepted
    viewpoint, driven home by the awesome power of the medical establishment, is that
    mammograms save women's life, and anyone who is against mammography is against
    women.

    Mammography is a multi-billion dollar industry. Several times in the past we tried to bring
    together an open debate with the proponents of the protocol, but they refused to
    participate. Of course, they know well that they wouldn't stand a chance. Mammography
    causes the rupture of blood vessels and cancer cell clusters in the breast, causing instant
    metastasis, it submits women to cumulative radiation that causes 10 to 20% higher rate of
    cancer among them in the course of a 10 year period, it has a rate of 30 to 40% error in
    cancer detection, and causes countless cases of completely needless biopsies and
    mastectomies with its false positive readings. This is a very dangerous medical procedure
    that should be declared illegal everywhere. Instead, it is hailed as the greatest hope in the
    fight against breast cancer.

    From the purely medical point of view, this scenario is utterly incomprehensible. From the
    corporate business model's point of view, it makes perfect sense, as long as you are willing
    to adopt a completely ruthless approach towards the patients. Our oncologists made that
    choice, and the industry prospers. This choice, as we will see, is not rooted in any
    malicious intent towards women, or towards the public in general. It is a business choice.
    It measures the welfare of the patient against the welfare of the corporate entity, and
    makes a choice in favour of the corporate side.  That is all. Nothing sinister, just plain
    business sense, not different from selling arms to third world countries, polluting the
    environment, or putting toxic sweeteners into soft drinks.

    Mammography fits nicely into the oncological corporate business model. One of its major
    advantages is that it cannot detect cancer at an early stage. By the time mammogram
    recognises the presence of a malignancy, it is too late for easy solutions. A positive reading
    is almost always followed by surgery and chemotherapy, which makes sense, because that
    is where the money is.

    Equally advantageous are the limitations of mammography when it is used to monitor the
    condition of breast cancer patients. It cannot detect cancer at a microscopic level, so by
    the time the recurrence is discovered, the cancer becomes a very serious threat. This
    necessitates a dramatic response, like mastectomy, removal of lymph nodes, high dose
    chemotherapy, and other heroic measures. This is where the situation becomes truly
    profitable, truly lucrative. Thus, mammography, as a widely practiced screening and
    monitoring technique, prevents cancer from being detected too early, and also prevents
    the early detection of its recurrence. No wonder it became the darling of the cancer
    industry. A large percent of oncological revenue depends on the lack of its efficacy, and on
    its harmful attributes.

    Someone may argue that bad as mammography may be as a screening test, there is
    nothing better available, is there? The answer is, yes, there are several better methods
    available, but I am only going to mention the one that is the most practical for breast
    cancer patients. It is called thermography, and it is able to detect cancer formation at the
    molecular level, 8-10 years before the cancer would show up in standard tests.
    Thermography is approved in your country by the FDA since 1982, it is no more expensive
    than a mammogram, it is very accurate, and it is non-invasive, gentle and harmless. No
    radiation and no drugs are involved. It is also suppressed very successfully by the medical
    establishment. If you ask an oncologist which method should be chosen, he will say that
    thermography has not been put through clinical trials (not true, how did it achieve
    approval?), that it is a dubious procedure (what does that mean?), and it cannot give any
    information to the doctor that mammograms cannot do better(absolutely false).

    It is interesting to note that the wide acceptance and utilization of thermography would
    put an end to the concept of 5-year survival. When you can detect cancer 10 years before
    it causes clinically observable symptoms, it stands to reason that it will be taken care of
    long before it can develop into a tumor. Once the patient is declared clear of cancer by a
    thermograph test, and the same test is showing negative results as it is repeated once a
    year, the 5-year survival concept loses its meaning. Both the patient and the doctor will
    know that the patient will be free of cancer worries for the rest of her life. This would deal
    a devastating blow to medical oncology as we know it today.

    Mammography is the major marketing tool of medical oncology, but the real profit comes
    from chemotherapy. It is a protocol that has been fine tuned to pull the most revenue out
    of the insurer or the taxpayer. What do we find, when we take a close look at the scary
    scenario of chemotherapy? In Italy, it is a fine mess. Here, in the United States, it has been
    reported in newspapers and journals, and discussed in congressional hearings that
    75% of the average American oncologist's revenue comes from the resale of
    chemotherapeutic drugs used in cancer therapy. It has also been established in
    independent university studies (Harvard and Michigan) involving  thousands of cases, that
    the vast majority of oncologists prefers to chose the drugs that pay the highest
    commission, regardless of the benefits to the patient. What a perplexing behavior for
    doctors; what a sensible attitude for a shrewd businessman!

    The chemotherapy/radiation protocol of medical oncology is most likely the largest and
    most lucrative deception ever perpetrated by organized medicine. It doesn't cure cancer; it
    suppresses it, while damaging the body and its immune system in very dangerous,
    occasionally lethal ways. High dose chemotherapy causes immune suppression, brain
    damage, injury to the heart muscles, leading to cardiac arrest, etc.  It causes horrific side
    effects, which should warn any sane person that something is very wrong with the
    treatment. The one thing chemotherapy doesn't accomplish is the elimination of cancer; it
    hasn't been designed to achieve that. It is an obscenely expensive procedure that ensures
    the recurrence of cancer within a shorter or longer period of time. Thus, the corporate
    desire of turning every case into a repeat business is fulfilled. Just treating the various
    damages and resulting health problems during and after chemotherapy provides oncology
    with significant further revenues. It is a devastating process for the patient, but a very
    satisfying enterprise from the corporate point of view.

    I have often stated in my writings and lectures that the standard oncological approach
    towards breast cancer is based on several falsehoods. To put it simply, the oncologist is
    lying to his or her patients. With these lies, and with the standard treatments based on
    them, we are condemning breast cancer patients to mutilation and death. What lies?

    "Cancer cells cannot be selectively targeted by anti-cancer drugs." This is the first
    fundamental lie.

    " In order to kill cancer cells, the treatment must use drugs that are toxic to all cells,
    normal and cancerous alike." This is the second pillar of oncological falsehood. It is a lie,
    and we know so since many decades.

    There exist gentle, non-toxic cancer therapies that are much more effective than the
    standard treatment, yet they are harmless and non-traumatic. They selectively target
    cancer cells, and do not, I repeat, do not poison healthy cells. Such treatments are legally
    and openly offered by medical doctors, medical oncologists, and naturopathic oncologists
    at a number of private clinics and medical offices in the United States and Canada, although
    very few patients have ever heard of them. Needless to say that the oncological community
    declares them quacks and hoaxsters. This is an important fact to consider, because it has
    far reaching consequences.

    We are looking at a scenario, where mainstream oncology is enforcing with all the financial
    and legal tools at its disposal a harmful, scientifically flawed treatment modality, while
    actively suppressing and publicly condemning effective and harmless protocols. As a result
    of this policy, over 600 thousand cancer patients died needlessly in the United States in
    2006. In the same year, 1.3 million new patients were diagnosed with the disease. This
    number, a major victory of oncological corporate planning, is the direct result of the
    suppression of effective and precise cancer screening among the American population. This
    is not an opinion, but a hard scientific fact.

    If we analyse the legal and social implications of this medical practice, it leads us to an
    uncharted, but very intriguing area. The members of corporate medicine, both at the
    clinical and the executive level, feel safe and secure. As long as they do everything by the
    book, regardless how the contents of that book have been created and legalized, they
    cannot be made accountable for the tragic results of their deeds, either individually or
    collectively. This shield of security, combined with a generous revenue, a guaranteed
    market share, and the status of being highly respected professionally and socially, lend a
    very comfortable and secure feeling to the members of corporate medicine. How well
    justified is that feeling?

    It is very well justified as long as society is willing to tolerate the presence of large scale
    medical racketeering. However, oncology as a hostile, self serving enterprise may be much
    more vulnerable than its perpetrators imagine.

    Here, in the United States, as well as in Canada, integrative medicine has made dramatic
    advances. New techniques, new equipment and new discoveries place progressive
    oncology far above the level of the allopathic medical practice. Quietly, without fanfare, the
    cancer care scenario is undergoing revolutionary changes. For example, it is not widely
    known that there are 10 states in the USA and 5 provinces in Canada - and the number is
    constantly  growing - where naturopathic physicians have the legislated right to give
    intravenous treatments. Even less people are aware of the fact that in 2004 a new
    specialty has been established in the American Association of Naturopathic Physicians:
    Naturopathic Oncology.

    This has tremendous importance. It means that now it is legal in 10 states of the United
    States for a naturopath to diagnose and treat cancer. It is now possible to change
    oncology from a medical monopoly, restricted to allopathic medicine, to a field that is open
    to integrative oncologists. This lifts it out from the charter of the AMA and the jurisdiction
    of the FDA and places it equally under the authority of integrative/naturopathic practice.

    Cancer care will take a new form in the hands of holistic and naturopathic physicians, and
    their methods will be protected by their legal rights. Tightly controlled clinical trials are
    being prepared as we speak, and once the results are published, allopathic oncology will
    find itself fighting for its very existence.

    What does this mean to the investment community?

    It means, Ladies and Gentlemen, that a huge investment opportunity is opening up in
    medicine, without legal battles and without public confrontation. There is no need to prove
    the superiority of non-toxic breast cancer treatments over the disastrous practice of
    allopathic oncology. Once the new treatments are offered to the public, the rest will be
    history. It is beyond the scope of this lecture to go into strategic details, but let me assure
    you that the field of cancer care, in North America, and everywhere else, will soon undergo
    a  profound change.

    In the second world war France relied on a defensive system called the Maginot line. This
    defensive fortification system was regarded as the heaviest and most powerful chain of
    defensive structures ever built. The Germans didn't attack it; they went around it, and
    conquered France. Something similar will happen to the awesome entity called allopathic
    oncology. It will be abandoned by its patients, without any confrontation, without
    accusations and courtroom battles.

    Investors and venture capitalists, please take note. Cancer is curable, and even more
    importantly, it is preventable. The cancer treatment of the future will happen in small
    clinics, or in the offices of holistic and naturopathic physicians. Toxic chemotherapy and
    mastectomy will become a thing of the past, remembered with a shudder. Chains of small
    clinics will spring up, some perhaps in the form of franchise operations, specializing on
    specific cancers, and offering highly advanced, effective protocols. There will be
    competition, and the cure rate will get closer and closer to 100%. The treatments will be
    non-toxic, and the cost will be a fraction of the present allopathic prices. Eventually, the
    insurance industry will be forced to recognize the treatments, and cover them in their
    policies.

    Savvy investors will steal the market from allopathic oncology before it will realize what is
    happening. Orthodox oncology as a medical specialty will collapse and disappear, and
    neither political clout, not billions of dollars will save it.

    Thank you for your attention, and if you wish to continue less formally, I will be glad to
    hear your comments and opinions. If you have questions, I will try to answer them to the
    best of my capabilities.

    (Discussion follows)